Characterization of host immune responses in Ebola virus infections

Expert Review of Clinical Immunology

Volumn 10, Issue 6, 2014, Pages 781-790

  Wong, Gary ^a,b   Kobinger, Gary P ^a,b,c   Qiu, Xiangguo ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adaptive immunity; antigenic subversion; Ebola; immunoevasion; innate immunity; long term immunity; secreted glycoprotein; type I IFN

Indexed keywords

CHEMOKINE; CYTOKINE; EBOLA VACCINE; INTERFERON;

ADAPTIVE IMMUNITY; EBOLA VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; REVIEW; SURVIVOR; VIROGENESIS; VIRUS INFECTION; VIRUS VIRULENCE; DOWN REGULATION; HEMORRHAGIC FEVER, EBOLA; IMMUNE EVASION; IMMUNOLOGY; PATHOLOGY;

DOWN-REGULATION; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNE EVASION; INTERFERON TYPE I;

EID: 84901068339     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.908705     Document Type: Review

References (96)

1. Gunther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011;204(Suppl 3):S785-90
2. Reed DS, Lackemeyer MG, Garza NL, et al. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect 2011;13(11): 930-6
3. Weingartl HM, Embury-Hyatt C, Nfon C, et al. Transmission of Ebola virus from pigs to non-human primates. Sci Rep 2012;2:811
4. Kobinger GP, Leung A, Neufeld J, et al. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J Infect Dis 2011;204(2):200-8
5. Marsh GA, Haining J, Robinson R, et al. Ebola Reston virus infection of pigs: clinical significance and transmission potential. J Infect Dis 2011;204(Suppl 3):S804-9
6. Nkoghe D, Leroy EM, Toung-Mve M, Gonzalez JP. Cutaneous manifestations of filovirus infections. Int J Dermatol 2012; 51(9):1037-43
7. Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley P, editors. Lippincott Williams and Wilkins; Philadelphia, PA, USA: 2013
8. Zampieri CA, Sullivan NJ, Nabel GJ. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol 2007;8(11):1159-64
9. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377(9768): 849-62
10. Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999;179(Suppl 1):S28-35
11. Rodriguez LL, De Roo A, Guimard Y, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1995;179(Suppl 1):S170-6
12. Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 2004;6(20):1-24
13. Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 2005;37(8): 1560-6
14. Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003;188(11):1618-29
15. Bosio CM, Aman MJ, Grogan C, et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003;188(11): 1630-8
16. Mahanty S, Hutchinson K, Agarwal S, et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003;170(6): 2797-801
17. Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002;80(3): 169-79
18. Zaki SR, Goldsmith CS. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 1999;235:97-116
19. Ebola haemorrhagic fever in Zaire. 1976. Bull World Health Organ 1978;56(2): 271-93
20. Kash JC, Muhlberger E, Carter V, et al. Global suppression of the host antiviral response by Ebola-and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 2006;80(6): 3009-20
21. Reid SP, Leung LW, Hartman AL, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006;80(11):5156-67
22. Reid SP, Valmas C, Martinez O, et al. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol 2007;81(24):13469-77
23. Basler CF, Mikulasova A, Martinez-Sobrido L, et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003; 77(14):7945-56
24. Chang TH, Kubota T, Matsuoka M, et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog 2009; 5(6):e1000493
25. Cardenas WB, Loo YM, Gale M Jr, et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 2006;80(11): 5168-78
26. Kimberlin CR, Bornholdt ZA, Li S, et al. Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc Natl Acad Sci USA 2010; 107(1):314-19
27. Leung DW, Prins KC, Borek DM, et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol 2010;17(2):165-72
28. Kuhl A, Pohlmann S. How Ebola virus counters the interferon system. Zoonoses Public Health 2012;59(Suppl 2):116-31
29. Schumann M, Gantke T, Muhlberger E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol 2009;83(17):8993-7
30. Jin H, Yan Z, Prabhakar BS, et al. The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J Gen Virol 2010; 91(Pt 2):352-61
31. Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 2001; 82(Pt 6):1365-73
32. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 2009;106(8):2886-91
33. Cook JD, Lee JE. The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog 2013;9(5): e1003258
34. Ou W, Delisle J, Jacques J, et al. Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. Virol J 2012;9:32
35. Francica JR, Varela-Rohena A, Medvec A, et al. Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein. PLoS Pathog 2010;6(9):e1001098
36. Noyori O, Matsuno K, Kajihara M, et al. Differential potential for envelope glycoprotein-mediated steric shielding of host cell surface proteins among filoviruses. Virology 2013;446(1-2):152-61
37. Groseth A, Marzi A, Hoenen T, et al. The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog 2012;8(8):e1002847
38. Mehedi M, Falzarano D, Seebach J, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol 2011;85(11):5406-14
39. Mohan GS, Li W, Ye L, et al. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog 2012;8(12):e1003065
40. Mahanty S, Gupta M, Paragas J, et al. Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology 2003;312(2):415-24
41. Bray M, Raymond JL, Geisbert T, Baker RO. 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res 2002;55(1):151-9
42. Gibb TR, Bray M, Geisbert TW, et al. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Pathol 2001;125(4):233-42
43. Geisbert TW, Hensley LE, Gibb TR, et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000;80(2):171-86
44. Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999;5(4): 423-6
45. Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis 2000;5(1):5-7
46. Wauquier N, Becquart P, Padilla C, et al. Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 2010;4:10
47. Baize S, Leroy EM, Georges AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002;128(1):163-8
48. Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis 2007; 196(Suppl 2):S357-63
49. Gupta M, MacNeil A, Reed ZD, et al. Serology and cytokine profiles in patients infected with the newly discovered Bundibugyo ebolavirus. Virology 2012; 423(2):119-24
50. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008; 82(11):5664-8
51. Warfield KL, Perkins JG, Swenson DL, et al. Role of natural killer cells in innate protection against lethal Ebola virus infection. J Exp Med 2004;200(2):169-79
52. Kim S, Iizuka K, Aguila HL, et al. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 2000;97(6):2731-6
53. Gupta M, Mahanty S, Bray M, et al. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J Virol 2001;75(10): 4649-54
54. Jones SM, Stroher U, Fernando L, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007;196(Suppl 2):S404-12
55. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11(7): 786-90
56. Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007;81(12):6379-88
57. Warfield KL, Swenson DL, Olinger GG, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196(Suppl 2):S430-7
58. Gupta M, Mahanty S, Greer P, et al. Persistent infection with Ebola virus under conditions of partial immunity. J Virol 2004;78(2):958-67
59. Olinger GG, Bailey MA, Dye JM, et al. Protective cytotoxic T-cell responses induced by Venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 2005;79(22):14189-96
60. Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011;17(9):1128-31
61. Gaufin T, Ribeiro RM, Gautam R, et al. Experimental depletion of CD8+ cells in acutely SIVagm-infected African Green Monkeys results in increased viral replication. Retrovirology 2010;7:42
62. Van Rompay KK, Blackwood EJ, Landucci G, et al. Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11. Virol J 2006;3:22
63. Warfield KL, Olinger G, Deal EM, et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005;175(2):1184-91
64. Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 2001;286(2):384-90
65. Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001;75(6):2660-4
66. Rao M, Bray M, Alving CR, et al. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol 2002;76(18):9176-85
67. Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola virus infection. Nat Med 1998;4(1):37-42
68. Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998;246(1): 134-44
69. Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 2012;109(13): 5034-9
70. Richardson JS, Yao MK, Tran KN, et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009;4(4):e5308
71. Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012;4(158):158ra146
72. Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 2013;110(5):1893-8
73. Marzi A, Yoshida R, Miyamoto H, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 2012;7(4):e36192
74. Qiu X, Audet J, Wong G, et al. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012; 4(138; 138ra181
75. Olinger GG Jr, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 2012;109(44): 18030-5
76. Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000; 355 (9222):2210-15
77. Leroy EM, Baize S, Debre P, et al. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 2001;124(3):453-60
78. Becquart P, Wauquier N, Mahlakoiv T, et al. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One 2010;5(2):e9126
79. Nkoghe D, Padilla C, Becquart P, et al. Risk factors for Zaire ebolavirus-specific IgG in rural Gabonese populations. J Infect Dis 2011;204(Suppl 3):S768-75
80. Qiu X, Audet J, Wong G, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep 2013;3:3365
81. Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit. Democratic Republic of the Congo 1995J Infect Dis 1999; 179(Suppl 1):S177-87
82. Ksiazek TG, West CP, Rollin PE, et al. A for the detection of antibodies to Ebola viruses. J Infect Dis 1999;179(Suppl 1): S192-8
83. Wauquier N, Becquart P, Gasquet C, Leroy EM. Immunoglobulin G in Ebola outbreak survivors, Gabon. Emerg Infect Dis 2009;15(7):1136-7
84. Sobarzo A, Ochayon DE, Lutwama JJ, et al. Persistent immune responses after Ebola virus infection. N Engl J Med 2013;369(5): 492-3
85. Sobarzo A, Groseth A, Dolnik O, et al. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J Infect Dis 2013;208(2):299-309
86. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010;207(10):2053-63
87. Prchal M, Pilz A, Simma O, et al. Type I interferons as mediators of immune adjuvants for T-and B cell-dependent acquired immunity. Vaccine 2009; 27(Suppl 6):G17-20
88. Smith LM, Hensley LE, Geisbert TW, et al. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis 2013;208(2):310-18
89. Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2009;2(1-2):12-17
90. Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 2010;6(5): e1000904
91. Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999;6(9):1574-83
92. Qiu X, Wong G, Fernando L, et al. mAbs and Ad-Vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 2013; 5(207):207ra143
93. ClinicalTrials.gov Experimental Vaccine for Prevention of Ebola Virus Infection 2014. Available from: http://clinicaltrials.gov/ct/show/NCT00374309
94. ClinicalTrials.gov Experimental Ebola Vaccine Trial 2014. Available from: http://clinicaltrials.gov/show/NCT00072605
95. ClinicalTrials.gov Ebola and Marburg Virus Vaccines. (2014). Available from: http://clinicaltrials.gov/ct2/show/NCT00605514
96. ClinicalTrials.gov Evaluating an Ebola and a Marburg Vaccine in Uganda. (2014). Available from http://clinicaltrials.gov/ct2/show/NCT00997607